PureTech's Deupirfenidone Shows Superiority in IPF Trial, Setting Stage for Phase 3 — PureTech Health plc

Event summary

PureTech Health's Phase 2b ELEVATE IPF trial results for deupirfenidone published in AJRCCM, showing 98.5% posterior probability of superiority vs. placebo in slowing FVC decline.
Deupirfenidone demonstrated statistically significant and clinically meaningful preservation of lung function, with a mean FVC difference of 91 mL vs. placebo (p=0.02).
Phase 3 SURPASS-IPF trial planned for H1 2026, comparing deupirfenidone head-to-head with pirfenidone for IPF treatment.
Deupirfenidone showed 50% greater drug exposure than pirfenidone with similar tolerability, maintaining 78.1% patient adherence over 26 weeks.

The big picture

PureTech's deupirfenidone represents a potential breakthrough in IPF treatment, addressing the historical tradeoff between efficacy and tolerability in antifibrotic therapies. The Phase 2b results position deupirfenidone as a candidate to set a new benchmark in a market where only ~25% of U.S. patients with IPF had received treatment as of 2019. The upcoming Phase 3 trial will be critical in determining whether deupirfenidone can disrupt the current standard of care dominated by pirfenidone and nintedanib.

What we're watching

Clinical Validation: Whether the Phase 2b results will translate into Phase 3 success, particularly in the head-to-head comparison with pirfenidone.
Market Differentiation: The pace at which deupirfenidone can establish itself as a next-generation antifibrotic, given the current limitations of existing IPF treatments.
Execution Risk: How PureTech's subsidiary Celea Therapeutics will manage the financing and initiation of the Phase 3 trial in H1 2026.